Company / R&D per Share
Travere Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.36
FY2025
5-year range
$0.12 / $3.81
FY2021-FY2025
Trend
-18.4%
vs FY2024
Sector context
#93 of 208
Health Care
What the data says
At $2.36, Travere Therapeutics, Inc.'s r&d per share ranks #93 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.12 in FY2022 to $3.81 in FY2023.
Based on SEC 10-K filings.
2.36 in FY2025 with a 5-year CAGR of -3.9%.
Declined from $3.81 to $2.36 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +169.7%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Sector benchmark
#93 of 208 in Health CareTop 45% of 208This company $2.36 Sector average $28.82
▼
-91.8% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 18.4% year-over-year.
- Ranks #93 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.36 | -18.4% |
| FY2024 | $2.89 | -24.3% |
| FY2023 | $3.81 | +3075.1% |
| FY2022 | $0.12 | -95.6% |
| FY2021 | $2.70 | -6.1% |
| FY2020 | $2.87 | +52.1% |
| FY2019 | $1.89 | +5.0% |
| FY2018 | $1.80 | +35.2% |
| FY2017 | $1.33 | +1.5% |
| FY2016 | $1.31 | -32.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026